Cabaletta Bio, Inc. (NASDAQ:CABA) Given Consensus Recommendation of “Moderate Buy” by Analysts

Cabaletta Bio, Inc. (NASDAQ:CABA) has received a consensus rating of “Moderate Buy” from the seven brokerages that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $17.00.

Several research analysts have recently issued reports on the company. Morgan Stanley decreased their target price on Cabaletta Bio from $14.00 to $13.00 and set an “overweight” rating for the company in a research report on Tuesday, March 24th. Wall Street Zen raised Cabaletta Bio from a “strong sell” rating to a “hold” rating in a research report on Sunday, March 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of Cabaletta Bio in a research report on Wednesday, January 21st. Finally, Guggenheim increased their target price on Cabaletta Bio from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th.

Insider Buying and Selling

In related news, CEO Steven Nichtberger acquired 45,000 shares of Cabaletta Bio stock in a transaction that occurred on Wednesday, January 21st. The stock was bought at an average price of $2.24 per share, with a total value of $100,800.00. Following the transaction, the chief executive officer directly owned 1,031,483 shares in the company, valued at approximately $2,310,521.92. This represents a 4.56% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Mark Simon acquired 11,061 shares of Cabaletta Bio stock in a transaction that occurred on Wednesday, January 21st. The shares were bought at an average cost of $2.28 per share, with a total value of $25,219.08. Following the transaction, the director owned 147,205 shares in the company, valued at $335,627.40. This represents a 8.12% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders purchased 127,668 shares of company stock worth $286,211 in the last 90 days. Corporate insiders own 11.25% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CABA. China Universal Asset Management Co. Ltd. bought a new position in Cabaletta Bio during the 4th quarter valued at approximately $34,000. CRA Financial Services LLC increased its position in Cabaletta Bio by 36.4% during the 3rd quarter. CRA Financial Services LLC now owns 15,000 shares of the company’s stock valued at $35,000 after buying an additional 4,000 shares in the last quarter. ANTIPODES PARTNERS Ltd bought a new position in Cabaletta Bio during the 4th quarter valued at approximately $38,000. Clear Harbor Asset Management LLC bought a new position in Cabaletta Bio during the 4th quarter valued at approximately $43,000. Finally, Jones Financial Companies Lllp bought a new position in Cabaletta Bio during the 3rd quarter valued at approximately $47,000.

Cabaletta Bio Stock Performance

Shares of NASDAQ:CABA opened at $3.13 on Monday. Cabaletta Bio has a 52-week low of $1.06 and a 52-week high of $3.78. The firm has a market capitalization of $348.43 million, a P/E ratio of -1.37 and a beta of 3.30. The stock has a 50 day moving average price of $2.96 and a 200-day moving average price of $2.63.

Cabaletta Bio (NASDAQ:CABA) last announced its earnings results on Monday, March 30th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.05. On average, equities analysts forecast that Cabaletta Bio will post -2.34 EPS for the current fiscal year.

About Cabaletta Bio

Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.

The company’s lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.